Grand Francis H, Hidalgo-Curtis Claire E, Ernst Thomas, Zoi Katerina, Zoi Christine, McGuire Carolann, Kreil Sebastian, Jones Amy, Score Joannah, Metzgeroth Georgia, Oscier David, Hall Andrew, Brandts Christian, Serve Hubert, Reiter Andreas, Chase Andrew J, Cross Nicholas C P
Wessex Regional Genetics Laboratory, Salisbury, United Kingdom.
Blood. 2009 Jun 11;113(24):6182-92. doi: 10.1182/blood-2008-12-194548. Epub 2009 Apr 22.
Recent evidence has demonstrated that acquired uniparental disomy (aUPD) is a novel mechanism by which pathogenetic mutations in cancer may be reduced to homozygosity. To help identify novel mutations in myeloproliferative neoplasms (MPNs), we performed a genome-wide single nucleotide polymorphism (SNP) screen to identify aUPD in 58 patients with atypical chronic myeloid leukemia (aCML; n = 30), JAK2 mutation-negative myelofibrosis (MF; n = 18), or JAK2 mutation-negative polycythemia vera (PV; n = 10). Stretches of homozygous, copy neutral SNP calls greater than 20Mb were seen in 10 (33%) aCML and 1 (6%) MF, but were absent in PV. In total, 7 different chromosomes were involved with 7q and 11q each affected in 10% of aCML cases. CBL mutations were identified in all 3 cases with 11q aUPD and analysis of 574 additional MPNs revealed a total of 27 CBL variants in 26 patients with aCML, myelofibrosis or chronic myelomonocytic leukemia. Most variants were missense substitutions in the RING or linker domains that abrogated CBL ubiquitin ligase activity and conferred a proliferative advantage to 32D cells overexpressing FLT3. We conclude that acquired, transforming CBL mutations are a novel and widespread pathogenetic abnormality in morphologically related, clinically aggressive MPNs.
最近的证据表明,获得性单亲二体(aUPD)是一种新机制,癌症中的致病突变可通过该机制纯合化。为了帮助识别骨髓增殖性肿瘤(MPN)中的新突变,我们进行了全基因组单核苷酸多态性(SNP)筛查,以鉴定58例非典型慢性髓性白血病(aCML;n = 30)、JAK2突变阴性的骨髓纤维化(MF;n = 18)或JAK2突变阴性的真性红细胞增多症(PV;n = 10)患者中的aUPD。在10例(33%)aCML和1例(6%)MF患者中发现了大于20Mb的纯合、拷贝中性SNP位点延伸,但PV患者中未发现。总共涉及7条不同的染色体,7q和11q在10%的aCML病例中均受影响。在所有3例11q aUPD病例中均鉴定出CBL突变,对另外574例MPN的分析显示,在26例aCML、骨髓纤维化或慢性粒单核细胞白血病患者中共有27个CBL变异体。大多数变异体是RING或连接域中的错义替换,这些替换消除了CBL泛素连接酶活性,并赋予过表达FLT3的32D细胞增殖优势。我们得出结论,获得性、转化性CBL突变是形态学相关、临床侵袭性MPN中一种新的广泛存在的致病异常。